Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 1, 2021

Study Completion Date

June 30, 2021

Conditions
Post-ERCP Acute Pancreatitis
Interventions
DRUG

Hemin

A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein

DRUG

placebo

A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein

Trial Locations (6)

1020

CHU Brugmann, Brussels

1070

Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels

6110

ISPPC CHU Vésale, Montigny-le-Tilleul

7000

Hôpital Ambroise Paré, Mons

7100

Centre Hospitalier de Jolimont-Lobbes, Haine-St-Paul

Unknown

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

Erasme University Hospital

OTHER

NCT01855841 - Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis | Biotech Hunter | Biotech Hunter